One-pot and one-step automated radio-synthesis of [18F]AlF-FAPI-74 using a multi purpose synthesizer: a proof-of-concept experiment
Sadahiro Naka, Tadashi Watabe, Thomas Lindner, Jens Cardinale, Kenta Kurimoto, Melissa Moore, Mitsuaki Tatsumi, Yuriko Mori, Eku Shimosegawa, Frank Valla Jr, Hiroki Kato, Frederik L Giesel, Sadahiro Naka, Tadashi Watabe, Thomas Lindner, Jens Cardinale, Kenta Kurimoto, Melissa Moore, Mitsuaki Tatsumi, Yuriko Mori, Eku Shimosegawa, Frank Valla Jr, Hiroki Kato, Frederik L Giesel
Abstract
Background: Fibroblast activation protein (FAP) is overexpressed in the stroma of many types of cancer. [18F]AlF-FAPI-74 is a positron emission tomography tracer with high selectivity for FAP, which has already shown high accumulation within human tumors in clinical studies. However, [18F]AlF-FAPI-74 radiosynthesis has not been optimized using an automated synthesizer. Herein, we report a one-pot and one-step automated radiosynthesis method using a multi purpose synthesizer.
Results: Radiosynthesis of [18F]AlF-FAPI-74 was performed using a cassette-type multi purpose synthesizer CFN-MPS200. After the recovery rate of trapped [18F]fluoride onto the anion-exchange cartridge using a small amount of eluent was investigated manually, a dedicated [18F]AlF-FAPI-74 synthesis cassette and synthesis program for one-pot and one-step fluorination was developed. The solutions for the formulation of [18F]AlF-FAPI-74 synthesized using this were evaluated to obtain stable radiochemical purity. The recovery rate of [18F]fluoride with only 300 µL of eluent ranged 90 ± 9% by introduction from the male side and elution from the female side of the cartridge. In automated synthesis, the eluted [18F]fluoride and precursor solution containing aluminum chloride were mixed; then, fluorination was performed in a one-pot and one-step process at room temperature for 5 min, followed by 15 min at 95 °C. As a result, the radioactivity of [18F]AlF-FAPI-74 was 11.3 ± 1.1 GBq at the end of synthesis from 32 to 40 GBq of [18F]fluoride, and its radiochemical yield was 37 ± 4% (n = 10). The radiochemical purity at the end of the synthesis was ≥ 97% for all formulation solutions. When the diluent was saline, the radiochemical purity markedly decreased after 4 h of synthesis. In contrast, with phosphate-buffered saline (pH 7.4) or 10 mM phosphate-buffered saline (pH 6.7) containing 100 mg of sodium ascorbate, the radiochemical purity was stable at 97%. Non-radioactive AlF-FAPI-74 and total impurities, including non-radioactive AlF-FAPI-74, were 0.3 ± 0.1 µg/mL and 2.8 ± 0.6 µg/mL. Ethanol concentration and residual DMSO were 5.5 ± 0.2% and 21 ± 6 ppm, respectively.
Conclusions: We established a one-pot one-step automated synthesis method using a CFN-MPS200 synthesizer that provided high radioactivity and stable radiochemical purity for possible clinical applications.
Keywords: Automated synthesis; Fibroblast activation protein; Positron emission tomography; [18F]AlF-FAPI-74.
Conflict of interest statement
The authors declare no potential conflicts of interest relevant to this article. FLGs are inventors and have patent rights.
© 2021. The Author(s).
Figures
References
- Allott L, Da Pieve C, Turton DR, Smith G. A general [18F]AlF radiochemistry procedure on two automated synthesis platforms. React Chem Eng. 2017;2:68–74. doi: 10.1039/C6RE00204H.
- Boschi S, Lee JT, Beykan S, Slavik R, Wei L, Spick C, Eberlein U, Buck AK, Lodi F, Cicoria G, Czernin J, Lassmann M, Fanti S, Herrmann K. Synthesis and preclinical evaluation of an Al 18 F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. Eur J Nucl Med Mol Imaging. 2016;43:2122–2130. doi: 10.1007/s00259-016-3437-y.
- Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012;11:257–266. doi: 10.1158/1535-7163.MCT-11-0340.
- D’Souza CA, McBride WJ, Sharkey RM, Todaro LJ, Goldenberg DM. High-yielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem. 2011;22(9):1793–1803. doi: 10.1021/bc200175c.
- Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jäger D, Flechsig P, Altmann A, Mier W, Haberkorn U. 68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60:386–392. doi: 10.2967/jnumed.118.215913.
- Giesel FL, Adeberg S, Syed M, Lindner T, Jiménez-Franco LD, Mavriopoulou E, Staudinger F, Tonndorf-Martini E, Regnery S, Rieken S, El Shafie R, Röhrich M, Flechsig P, Kluge A, Altmann A, Debus J, Haberkorn U, Kratochwil C. FAPI-74 PET/CT using either 18 F-AlF or cold-kit 68 Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients. J Nucl Med. 2021;62:201–207. doi: 10.2967/jnumed.120.245084.
- Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8:454–463. doi: 10.1002/prca.201300095.
- Kersemans K, De Man K, Courtyn J, Van Royen T, Piron S, Moerman L, Brans B, De Vos F. Automated radiosynthesis of Al[18 F]PSMA-11 for large scale routine use. Appl Radiat Isot. 2018;135:19–27. doi: 10.1016/j.apradiso.2018.01.006.
- Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK. (68)Ga. 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801–805. doi: 10.2967/jnumed.119.227967.
- Kratochwil C, Giesel FL, Rathke H, Fink R, Dendl K, Debus J, Mier W, Jäger D, Lindner T, Haberkorn U. [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma. Eur J Nucl Med Mol Imaging. 2021 doi: 10.1007/s00259-021-05273-8.
- Malik N, Baur B, Winter G, Reske SN, Beer AJ, Solbach C. Radiofluorination of PSMA-HBED via Al(18)F(2+) chelation and biological evaluations in vitro. Mol Imaging Biol. 2015;17(6):777–785. doi: 10.1007/s11307-015-0844-6.
- McBride WJ, Sharkey RM, Karacay H, D’Souza CA, Rossi EA, Laverman P, Chang CH, Boerman OC, Goldenberg DM. A novel method of 18F radiolabeling for PET. J Nucl Med. 2009;50:991–998. doi: 10.2967/jnumed.108.060418.
- McBride WJ, D’Souza CA, Sharkey RM, Karacay H, Rossi EA, Chang CH, Goldenberg DM. Improved 18F labeling of peptides with a fluoride–aluminum-chelate complex. Bioconjug Chem. 2010;21:1331–1340. doi: 10.1021/bc100137x.
- Naka S, Watabe T, Kurimoto K, Uemura M, Soeda F, Neels OC, Kopka K, Tatsumi M, Kato H, Nonomura N, Shimosegawa E, Cardinale J, Giesel FL, Hatazawa J. Automated [18 F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination. EJNMMI Radiopharm Chem. 2020;5:18. doi: 10.1186/s41181-020-00101-0.
- Spreckelmeyer S, Balzer M, Poetzsch S, Brenner W. Fully-automated production of [68Ga]Ga-FAPI-46 for clinical application. EJNMMI Radiopharm Chem. 2020;5(1):31. doi: 10.1186/s41181-020-00112-x.
- Tshibangu T, Cawthorne C, Serdons K, Pauwels E, Gsell W, Bormans G, Deroose CM, Cleeren F. Automated GMP compliant production of [18F]AlF-NOTA-octreotide. EJNMMI Radiopharm Chem. 2020;5:4. doi: 10.1186/s41181-019-0084-1.
- Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K, Toyoshima A, Nagata K, Shimosegawa E, Haberkorn U, Kratochwil C, Shinohara A, Giesel F, Hatazawa J. Theranostics targeting fibroblast activation protein in the tumor stroma: 64 Cu- and 225 Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models. J Nucl Med. 2020;61:563–569. doi: 10.2967/jnumed.119.233122.
- Zlatopolskiy B, Zischler J, Krapf P, Zarrad F, Urusova E, Kordys E, Endepols H, Neumaier B. Copper-mediated aromatic radiofluorination revisited: efficient production of PET tracers on a preparative scale. Chem. 2015;21:5972–5979. doi: 10.1002/chem.201405586.
Source: PubMed